Latest MS research news

Latest MS research news | 09 October 2013

Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive MS

This study from Denmark investigated if different MS subtypes would show differences in gene expression which may be linked to specific subsets of peripheral blood mononuclear cells (PBMCs).

From MSIF

Latest MS research news | 30 September 2013

Endurance training is feasible in severely disabled patients with progressive multiple sclerosis

This Danish study looked at upper-body endurance training (ET) in severely disabled people with progressive MS, firstly to see if it is feasible and secondly to see if the intensity is high enough to induce cardiovascular adaptations.

From MSIF

Latest MS research news | 30 September 2013

Patterns and predictors of naturally occurring change in depressive symptoms over a 30-month period in multiple sclerosis

This study looked at the changes in depressive symptoms in 269 people with RRMS over a 30-month period as well as the demographic, clinical and behavioural predictors of these changes.

From MSIF

Latest MS research news | 30 September 2013

Circulating dendritic cells of MS patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors

Dendritic cells (DC) are innate immune cells and may play a role in the pathogenesis of MS. Due to their specialised antigen-presenting capacity; DCs provide an important link ...

From MSIF

Latest MS research news | 24 September 2013

Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis

The primary question the research group addressed was if perfusion MRI in early RRMS might detect a reduction in grey matter (GM) perfusion in the absence of GM atrophy, which may potentially indicate a reversible ...

From MSIF

Latest MS research news | 24 September 2013

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis

This study from Sweden looked at the changes in the T-cell receptor (TCR) repertoire in both CSF and peripheral blood in people with MS treated with natalizumab for at least 18 months.

From MSIF

Latest MS research news | 24 September 2013

Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration

N-acetylasparate (NAA) is a neuronal marker. Based on this, the researchers in the study examined if people with benign MS (BMS) had similar losses of global NAA relative to more ...

From MSIF

Latest MS research news | 17 September 2013

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

The original phase III trial looked at oral laquinimod in 1106 people with RRMS.

From MSIF

Latest MS research news | 17 September 2013

Brain atrophy and lesion load predict long term disability in multiple sclerosis

This retrospective study as part of the MAGNIMS collaboration looked at MR imaging at baseline and after one year and two years as well as EDSS scores at baseline and after ten years in 261 people with MS.

From MSIF

Latest MS research news | 17 September 2013

Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis

This study from the Netherlands looked at the validity and reliability over time of the Symbol Digit Modality Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) ...

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial